Implications of new anticoagulants in primary practice

International Journal of Clinical Practice

Volumn 67, Issue 2, 2013, Pages 139-156

  Perez, A ^a   Eraso, L H ^a   Merli, G J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; DRONEDARONE; ENOXAPARIN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84872356086     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12023     Document Type: Review

References (88)

1. Geerts WH, Bergqvist D, Pineo GF, et al., Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 381S-453S.
2. Kearon C, Kahn SR, Agnelli G, et al., Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 454S-545S.
3. DeCaterina R,. The current role of anticoagulants in cardiovascular medicine. J Cardiovasc Med (Hagerstown) 2009; 10: 595-604.
4. Ansell J, Hirsh J, Hylek E, et al., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 160S-98S.
5. Ageno W,. Recent advances in the management of venous thromboembolism. Korean J Hematol 2010; 45: 8-13.
6. Eriksson BI, Quinlan DJ, Eikelboom JW,. Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011; 62: 41-57.
7. Eriksson BI, Quinlan DJ, Weitz JI,. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and Factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 1-22.
8. FDA once again delays approval of apixaban (Eliquis). 2012. http://cardiobrief.org/2012/06/25/fda-once-again-delays-approval-of-apixaban- eliquis/. (accessed July 2012).
9. ® (rivaroxaban) granted priority review by US FDA to prevent secondary cardiovascular events in patients with ACS. 2012. http://press.bayerhealthcare.com/en/press/auth/news-details- page.php/14505/2012-0089. (accessed May 2012).
10. FDA rejects ACS indication for rivaroxaban (Xarelto). 2012. http://cardiobrief.org/2012/06/21/fda-rejects-acs-indication-for-rivaroxaban- xarelto/. (accessed July 2012).
11. Eriksson BI, Borris LC, Friedman RJ, et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-75.
12. Kakkar AK, Brenner B, Dahl OE, et al., Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-9.
13. Lassen MR, Ageno W, Borris LC, et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-86.
14. Turpie AGG, Lassen MR, Davidson BL, et al., Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-80.
15. Turpie AGG, Lassen MR, Eriksson BI, et al., Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-53.
16. Lassen MR, Raskob GE, Gallus A, et al., Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
17. Lassen MR, Raskob GE, Gallus A, et al., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-15.
18. Lassen MR, Gallus A, Raskob GE, et al., Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
19. Eriksson BI, Dahl OE, Rosencher N, et al., Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
20. Eriksson BI, Dahl OE, Rosencher N, et al., Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
21. Eriksson BI, Dahl OE, Huo MH, et al., Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-9.
22. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
23. Friedman RJ, Dahl OE, Rosencher N, et al., Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010; 126: 175-82.
24. Anderson FA, Jr, Spencer FA,. Risk factors for venous thromboembolism. Circulation 2003; 107: I9-16.
25. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al., Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167-77.
26. Cohen AT, Spiro TE, Büller HR, et al., Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. American College of Cardiology Congress 60th Annual Scientific Session. New Orleans, USA, 2-5 April 2011; Oral presentation.
27. Cohen AT, Spiro TE, Büller HR, et al., Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31: 407-16.
28. Oger E,. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-60.
29. Prandoni P, Lensing AWA, Cogo A, et al., The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
30. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
31. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
32. Botticelli Investigators, Buller H, Deitchman D, Prins M, Segers A,. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-8.
33. Schulman S, Kearon C, Kakkar AK, et al., Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
34. Schulman S, Kakkar AK, Schellong SM, et al., A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 205.
35. Schulman S, Ericsson H, Goldhaber SZ, et al., Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9 (Suppl. 2):731. Abstract O-TH-033.
36. Schulman S, Baanstra D, Eriksson H, et al., Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011; 9 (Suppl. 2):22. Abstract O-MO-037.
37. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
38. Singer DE, Albers GW, Dalen JE, et al., Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 546S-92S.
39. Camm AJ, Kirchhof P, Lip GYH, et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
40. You JJ, Singer DE, Howard PA, et al., Antithrombotic therapy for atrial fibrillation. Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition). Chest 2012; 141: 531S-75S.
41. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-7.
42. Hacke W, Patel MR, Becker RC, et al., Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies. 19th European Stroke Conference. Barcelona, Spain. 2010; Poster OAID 5.
43. Patel MR, Mahaffey KW, Garg J, et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
44. Melamed OC, Horowitz G, Elhayany A, Vinker S,. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care 2011; 17: 232-7.
45. Wieloch M, Sjalander A, Frykman V, et al., Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32: 2282-9.
46. Connolly SJ, Ezekowitz MD, Yusuf S, et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
47. Lopes RD, Alexander JH, Al-Khatib SM, et al., Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-9.
48. Ansell J, Hollowell J, Pengo V, et al., Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007; 23: 83-91.
49. Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) Prescribing Information. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202439s001lbl.pdf. (accessed July 2012).
50. ® (rivaroxaban) Summary of Product Characteristics. 2012. http://www.xarelto.com/html/downloads/Xarelto- Prescribing-Information-May-2012.pdf. (accessed July 2012).
51. Eikelboom JW, O'Donnell M, Yusuf S, et al., Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010; 159: 348-53.
52. Connolly SJ, Eikelboom J, Joyner C, et al., Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
53. Granger CB, Alexander JH, McMurray JJ, et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
54. Ezekowitz MD, Connolly S, Parekh A, et al., Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-10.
55. Connolly GC, Khorana AA,. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl. 2): S1-7.
56. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L,. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-6.
57. Beasley BN, Unger EF, Temple R,. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011; 364: 1788-90.
58. Paikin JS, Haroun MJ, Eikelboom JW,. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther 2011; 9: 279-86.
59. Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2011. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000829/WC500041059.pdf. (accessed July 2012).
60. Van de Werf F,. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur Heart J 2009; 30: 1695-702.
61. Mega JL, Braunwald E, Mohanavelu S, et al., Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374: 29-38.
62. Gibson CM, Mega JL, Burton P, et al., Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011; 161: 815-21.
63. Mega JL, Braunwald E, Wiviott SD, et al., Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
64. The APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-85.
65. Alexander JH, Becker RC, Bhatt DL, et al., Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 2877-85.
66. Alexander JH, Lopes RD, James S, et al., Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699-708.
67. Wisler JW, Becker RC,. Oral factor Xa inhibitors for the long-term management of ACS. Nat Rev Cardiol 2012; 21: 392-401.
68. Oldgren J, Budaj A, Granger CB, et al., Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32: 2781-9.
69. Phillips KW, Ansell J,. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost 2010; 103: 34-9.
70. Garcia D, Libby E, Crowther MA,. The new oral anticoagulants. Blood 2010; 115: 15-20.
71. Balaratnam S,. Prevention and treatment of thromboembolic events in medical patients and new anticoagulants. Acta Clin Belg 2009; 64: 547-52.
72. US Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): drug safety communication-safety review of post-market reports of serious bleeding events. 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm282820.htm. (accessed May 2012).
73. Uchino K, Hernandez AV,. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
74. Radecki RP,. Dabigatran: uncharted waters and potential harms. Ann Intern Med 2012; 157: 66-8.
75. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G,. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-21.
76. Frost C, Yu Z, Nepal S, et al., Apixaban, a direct Factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008; 48:1132. Abstract 142.
77. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-99.
78. Ma Q,. Development of oral anticoagulants. Br J Clin Pharmacol 2007; 64: 263-5.
79. Yacobi A, Udall JA, Levy G,. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976; 19: 552-8.
80. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M,. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-80.
81. Raghavan N, Frost CE, Yu Z, et al., Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81.
82. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
83. Bristol-Myers Squibb. Coumadin tablets (warfarin sodium) Prescribing information. 2010. http://packageinserts.bms.com/pi/pi-coumadin.pdf. (accessed May 2012).
84. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D,. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos 2009; 37: 1056-64.
85. Stangier J,. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
86. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F,. The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov 2011; 10: 61-75.
87. Paikin JS, Eikelboom JW, Cairns JA, Hirsh J,. New antithrombotic agents-insights from clinical trials. Nat Rev Cardiol 2010; 7: 498-509.
88. Tadros R, Shakib S,. Warfarin - indications, risks and drug interactions. Aust Fam Physician 2010; 39: 476-9.